NovoCure Ltd. (NVCR) PT Raised to $75 at JPMorgan, Following Earnings
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
JPMorgan analyst Cory Kasimov raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $75.00 (from $73.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reliance Industries (RIL:IN) PT Raised to INR2,250 at JPMorgan
- ICICI Securities Upgrades Ashok Leyland Ltd. (AL:IN) to Buy (1)
- UPDATE: BlackBerry (BB) Reports In-Line Q1 EPS
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesJPMorgan, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!